低密度脂蛋白胆固醇,他类药物治疗和大脑微型血液:CIRCLE研究
Yuqi Zhao1, Ying Zhou1, Huan Zhou1
1Department of Neurology, the 2nd Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, China.
NeuroImage. Clinical
|August 29, 2023
概括
非常低的LDL-C水平与更多的大脑微型血液 (CMB) 有关. 然而,使用他类药物,特别是阿托瓦斯塔丁,并没有增加CMB风险,并且可能在没有中风的个人中提供保护.
科学领域:
- 神经学 神经学
- 心血管研究研究心血管研究
- 生物化学 生物化学
背景情况:
- 大脑微型血流 (CMB) 与心血管风险因素有关.
- 低密度脂蛋白胆固醇 (LDL-C) 水平,他类药物使用和CMB之间的关系尚未完全理解.
- 这项研究在没有中风的人群中调查了这些关联.
研究的目的:
- 为了前性地研究LDL-C水平与新型CMB的发生率之间的关系.
- 评估他类药物使用对在无中风队列中新型CMBs发展的影响.
主要方法:
- 对209名没有中风的,有脑小血管疾病标志物的人进行前性队列研究 (CIRCLE研究).
- 基线LDL-C水平被分为四分位数.
- 用敏感度加权成像 (SWI) 进行为期一年的随访,以检测新的CMB (叶叶和深层).
主要成果:
- 新深层CMB的发病率在最低的LDL-C四分位数 (Q1: ≤1.76 mmol/L) 中最高,为30.0%.
- 较低的LDL-C (Q1) 与新的深层CMB的发病率增加显著相关 (OR=4.256,p=0.029).
- 在没有先前使用他类药物的参与者中,阿托瓦斯塔丁的使用与减少新的深层CMB相关 (OR=0.181,p=0.040),而罗斯瓦斯塔丁没有显著影响.
结论:
- 较低的LDL-C水平与较高的新深层CMBs发病率有关.
- 立方体治疗,特别是阿托瓦斯塔丁,可能会对新的CMB发展产生保护作用.
- 这些发现表明,他类药物不会增加CMB风险,在某些人群中可能是有益的.
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
697
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
697
01:26Coronary Artery Disease IV: Preventive Measures
23
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
23
01:26Atherosclerosis III: Management
12
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
12
01:25Blood Studies for Cardiovascular System III: Serum Lipid Profile
190
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
190
01:30Atherosclerosis I: Introduction
10
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
10